NYSEAMERICAN:PTHS Pelthos Therapeutics (PTHS) Stock Price, News & Analysis $20.29 +0.77 (+3.94%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Pelthos Therapeutics Stock (NYSEAMERICAN:PTHS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pelthos Therapeutics alerts:Sign Up Key Stats Today's Range$19.52▼$20.8950-Day Range$19.42▼$29.4552-Week Range$18.19▼$37.50Volume51,819 shsAverage Volume36,026 shsMarket Capitalization$77.71 millionP/E RatioN/ADividend YieldN/APrice Target$52.83Consensus RatingModerate Buy Company Overview Pelthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines. Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available. Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited. Pelthos Therapeutics is headquartered in the United States and its activities are primarily focused on pharmaceutical research and development.AI Generated. May Contain Errors. Read More Pelthos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScorePTHS MarketRank™: 3.064070517035 of 5 starsPelthos Therapeutics scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingPelthos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPelthos Therapeutics has a consensus price target of $52.83, representing about 160.4% upside from its current price of $20.29.Amount of Analyst CoveragePelthos Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Pelthos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pelthos Therapeutics are expected to grow in the coming year, from ($15.22) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pelthos Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pelthos Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPelthos Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.27% of the float of Pelthos Therapeutics has been sold short.Short Interest Ratio / Days to CoverPelthos Therapeutics has a short interest ratio ("days to cover") of 4.07.Change versus previous monthShort interest in Pelthos Therapeutics has recently increased by 11.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPelthos Therapeutics does not currently pay a dividend.Dividend GrowthPelthos Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.42 News SentimentPelthos Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Pelthos Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for PTHS on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Pelthos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pelthos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,434.00 in company stock.Percentage Held by Insiders16.40% of the stock of Pelthos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.96% of the stock of Pelthos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pelthos Therapeutics' insider trading history. Receive PTHS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pelthos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTHS Stock News HeadlinesPelthos Therapeutics (NYSEAMERICAN:PTHS) Stock: Insider Ezra Friedberg Sells 558 SharesOctober 8, 2026 | americanbankingnews.comPelthos Therapeutics Inc. Signs Agreement with Major Pharmacy Benefit Manager to Open Access to Zelsuvmi Topical Gel, 10.3%October 7, 2026 | marketscreener.comMLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 13 at 1:00 AM | InvestorPlace (Ad)Insider Selling: Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells 558 Shares of Company StockOctober 7, 2026 | insidertrades.comPelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%October 6, 2026 | globenewswire.comAnalysts Offer Insights on NA Companies: Pelthos Therapeutics (PTHS) and X-Energy, Inc. Class A (XE)September 16, 2026 | theglobeandmail.comPelthos (PTHS) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | finance.yahoo.comPelthos Therapeutics Inc. Q2 2026 Earnings Call SummaryAugust 14, 2026 | finance.yahoo.comSee More Headlines PTHS Stock Analysis - Frequently Asked Questions How have PTHS shares performed this year? Pelthos Therapeutics' stock was trading at $25.94 at the beginning of 2026. Since then, PTHS shares have decreased by 21.8% and is now trading at $20.29. How were Pelthos Therapeutics' earnings last quarter? Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) released its earnings results on Thursday, August, 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. The company earned $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative trailing twelve-month return on equity of 204.71%. Read the conference call transcript. How do I buy shares of Pelthos Therapeutics? Shares of PTHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PTHS's financial health is in the Green zone, according to TradeSmith. PTHS has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:PTHS CIK1919246 Webwww.pelthos.com Phone(919) 908-2422FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Price Target for Pelthos Therapeutics$52.83 High Price Target$64.00 Low Price Target$40.00 Potential Upside/Downside+160.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.32 million Net Margins-165.24% Pretax Margin-216.56% Return on Equity-204.71% Return on Assets-43.59% Debt Debt-to-Equity Ratio3.40 Current Ratio1.98 Quick Ratio1.31 Sales & Book Value Annual Sales$16.80 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$12.02 per share Price / Book1.69Miscellaneous Outstanding Shares3,830,000Free Float3,201,000Market Cap$77.71 million OptionableN/A Beta3.07 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSEAMERICAN:PTHS) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pelthos Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pelthos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
